CA Patent

CA2491445A1 — Compositions and methods for reduction of inflammatory symptoms and/or biomarkers in female subjects

Assigned to Galileo Pharmaceuticals Inc · Expires 2004-01-15 · 22y expired

What this patent protects

Medicaments and methods for the treatment and/or amelioration of certain inflammatory symptoms related to premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), perimenopause, menopause, endometriosis, post-partum depression, or administration of hormonal contracept…

USPTO Abstract

Medicaments and methods for the treatment and/or amelioration of certain inflammatory symptoms related to premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), perimenopause, menopause, endometriosis, post-partum depression, or administration of hormonal contraceptives are described herein. Medicaments of the invention comprise a tocopherol, an omega-3 poly-unsaturated fatty acid, such as docosahexaenoic acid (DHA), or omega-9 polyunsaturated fatty acid, optionally, a flavonoid, and, optionally, a mineral, such as magnesium. Methods for treating or ameliorating such symptoms and methods for reducing elevated CRP and/or white blood cell (WBC) associated with such conditions using medicaments of the invention are also described.

Drugs covered by this patent

Patent Metadata

Patent number
CA2491445A1
Jurisdiction
CA
Classification
—
Expires
2004-01-15
Drug substance claim
No
Drug product claim
No
Assignee
Galileo Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.